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Background: Generic health-related quality of life (HRQoL) scales are increasingly being
used to assess the effects of new treatments in schizophrenia. The objective of this study is to
better understand the usefulness of generic and condition specific HRQoL scales in schizo-
phrenia by analyzing their correlates.
Methods: Data formed part of the Pattern study, an international observational study among
1379 outpatients with schizophrenia. Patients were evaluated with the Mini International
Neuropsychiatric Inventory, the Clinical Global Impression-Schizophrenia (CGI-SCH) Scale
and the Positive and Negative Syndrome Scale (PANSS) and reported their HRQoL using the
Schizophrenia Quality of Life Scale (SQLS), the Short Form-36 (SF-36), and the EuroQol-5
Dimension (EQ-5D). The two summary values of the SF-36 (the Mental Component Score
and the Physical Component Score, SF-36 MCS and SF-36 PCS) were calculated.
Results: Higher PANSS positive dimension ratings were associated with worse HRQoL for
the SQLS, EQ-5D VAS, SF-36 MCS, and SF-36 PCS. Higher PANSS negative dimension
ratings were associated with worse HRQoL for the EQ-5D VAS, SF-36 MCS, and SF-36
PCS, but not for the SQLS or the EQ-5D tariff. PANSS depression ratings were associated
with lower HRQoL in all the scales. There was a high correlation between the HRQoL
scales. However, in patients with more severe cognitive/disorganized PANSS symptoms, the
SQLS score was relatively higher than the EQ-5D tariff and SF-36 PCS scores.
Conclusion: This study has shown substantial agreement between three HRQoL scales,
being either generic or condition specific. This supports the use of generic HRQoL measures
in schizophrenia.
Clinicaltrials.gov identifier: NCT01634542 (July 6, 2012, retrospectively registered).
Keywords: schizophrenia, health-related quality of life, epidemiology, persistent symptoms
Introduction
Schizophrenia is a severe, disabling, stigmatizing and frequently chronic condition
which impacts on the social, occupational and everyday functioning of the indivi-
duals who suffer from it. Assessing health-related quality of life (HRQoL) in
schizophrenia is necessary to understand which aspects of the disorder are mean-
ingful for the patients themselves.
Instruments that measure HRQoL in mental health have been increasingly
introduced to clinical practice as a good method to monitor treatment results,
functioning, and quality of life.1,2 Treatment for schizophrenia should aim at
improving patients’ health-related quality of life (HRQoL), as this may be asso-
ciated with increased satisfaction with care and higher adherence.3 Moreover,
identifying the factors that are correlated with reduced quality of life is essential
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to optimize the treatment and the management of comor-
bidities. Accordingly, it is necessary to incorporate self-
reported HRQoL measures when assessing treatment
outcomes among patients with schizophrenia. These
HRQoL instruments ask patients to report their perspective
on their health status.
There is currently a debate about which measurements
better reflect the HRQoL of patients with schizophrenia.4
HRQoL can be measured either with generic or with con-
dition specific HRQoL scales. Generic scales have been
developed to measure HRQoL across different health con-
ditions while condition-specific scales focus on the symp-
toms and difficulties experienced by individuals presenting
a particular health problem.
The capacity of generic HRQoL scales to reliably
assess QoL has been questioned.5,6 In their review of the
validity of generic HRQoL measures in schizophrenia,
Papaioannou et al.5 cast doubts upon the EQ-5D and the
SF-36, the most frequently used generic HRQoL scales,
being sensitive to symptom severity of the disorder.
Specifically, when assessing the relationship between
HRQoL and positive and negative symptoms of schizo-
phrenia they found ten studies suggesting uncertain or no
evidence of an association, whereas only four revealed
moderate, to strong, correlations between these symptoms
and generic HRQoL measures. They also reported that the
correlation of generic HRQoL scales with depression
symptoms seemed to be stronger than the correlation of
generic HRQoL scales with positive and negative symp-
toms of schizophrenia. Additionally, previous studies have
also provided inconsistent findings on the relationship
between generic HRQoL measures and patient function-
ing: four studies found a strong relationship between
HRQoL and functioning7–10 and four described uncertain
or no evidence of such a relationship.11–14 However, the
relative lack of agreement between HRQoL scales and
symptom severity and functioning should be expected
given that HRQoL covers many more dimensions than
these two concepts.15 In spite of being an extensive and
comprehensive review, Papaioannou et al work has also
some shortcomings. For example, the included studies had
very heterogeneous patient populations, in the sense that
patients were in different stages of illness and treatment
settings.
More recently, Mulhern et al used seven existing data-
sets to analyze the psychometric properties of the EQ-5D
and the SF-36 in the assessment of individuals with mental
disorders. Two of these studies included about three
hundred individuals with schizophrenia.16,17 They found
unclear evidence that generic HRQoL scales were valid in
schizophrenia and concluded that there was some support
for the construct validity of generic HRQoL scales in
assessing patients with schizophrenia, but that responsive-
ness was low.18
Finally, the utility of HRQoL scales in schizophrenia
has also been criticized on other grounds, which are com-
mon for generic and disorder-specific scales. In particular,
many clinicians think that patients may frequently be too
unwell, psychotic, or disturbed to be reliable in the self-
assessment of their health status. Additionally, self-
reported health measures may be of special concern in
individuals with cognitive impairment, as those suffering
from schizophrenia. There is limited data on the validity
and consistency of HRQoL questionnaires in individuals
with cognitive problems.19 Finally, HRQoL may be influ-
enced by expectations and adaptation to illness mechan-
isms in individuals with chronic conditions, who may tend
to rate HRQoL higher than individuals with the same
disability but caused by more acute illness.20
In spite of these limitations, the use of generic HRQoL
scales in schizophrenia has relevant support. Regulatory
bodies in the USA, the UK, and France endorse the inclu-
sion of HRQoL measures in assessing treatment effects in
individuals with chronic health conditions.19 Since health-
policy decisions are taken for all health conditions, these
agencies rely mostly on the generic HRQoL measures such
as the EQ-5D21 and the SF-3622 For these reasons, generic
HRQoL scales are increasingly being used to test the
effectiveness of new treatments.
Given the relevance of assessing QoL in schizophrenia,
the fact that generic scales are used to determine if a given
treatment impacts on HRQoL in schizophrenia, coupled
with the inconsistent literature findings on HRQoL deter-
minants, and the need to better understand the meaning
and correlates of generic HRQoL measures in schizophre-
nia, our study aims to: a) analyze the relationship between
generic and schizophrenia-specific HRQoL scales in
patients with schizophrenia and b) describe the clinical
factors that influence HRQoL in these patients.
Materials and Methods
Study Design
The objective of these post-hoc analyses of the Pattern
study23 is to increase the understanding of the usefulness
of two generic HRQoL scales (SF-36 and EQ-5D) in
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evaluating patients with schizophrenia. We will analyze
the socio-demographic and clinical correlates associated
with the rating of these two scales, especially how they
relate to symptom severity of schizophrenia. We will also
compare them to one condition specific HRQoL
(Schizophrenia Quality of Life Scale). Data for these ana-
lyses were obtained from the Pattern study, a multicentric
observational study that assessed the care and clinical
outcomes of outpatients with schizophrenia in 8 countries
(Argentina, Brazil, Canada, France, Germany, Italy, Spain,
and the United Kingdom).
Individuals with schizophrenia of at least 18 years old
who were receiving care in an outpatient setting were
eligible for study entry. Participants had to meet diagnostic
criteria for schizophrenia according to the Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edition, Text
Revision or the International Classification of Diseases, 10th
Revision.24 To confirm the diagnosis, a reduced version of
the Mini International Neuropsychiatric Inventory25 was
administered by the participating psychiatrists. Individuals
with a recent psychotic exacerbation (three months prior to
baseline), those who were enrolled in an interventional
study at baseline, and those who were unable or unwilling
to comply with the study protocol were not eligible for
inclusion. For this study, a recent psychotic exacerbation
was defined as hospitalization or increased psychiatric care
in order to avoid hospitalization. No other exclusion criteria
were applied in order to achieve a high generalizability of
the findings.
Recruitment and evaluation were conducted by psy-
chiatrists working in outpatient facilities and the psychia-
trist’s teams. Patients were recruited using a sequential
selection procedure. From the list of patients being treated
at each of the participating clinical sites, those individuals
who fulfilled the inclusion criteria and did not have any
exclusion criteria were invited to participate. Patient care
was solely at the discretion of the treating psychiatrist.
There were no instructions regarding treatment in the
study protocol. The protocol and consent procedures
were approved by all local institutional review boards/
ethics committees before study initiation. All patients
voluntarily participated in the study and provided
informed consent.
Patient Assessment
Participating psychiatrists with, in some cases, the colla-
boration of adequately trained mental health profes-
sionals of their teams, evaluated the patients using an
electronic hand-held tablet. This assessment included
socio-demographic and clinical variables, Positive and
Negative Syndrome Scale (PANSS),26 and the Clinical
Global Impression-Schizophrenia (CGI-SCH) Scale.
Participating psychiatrists and the members of their
teams who completed assessments were provided with
training in the use of the questionnaires. PANSS dimen-
sions were calculated based on Lindenmayer et al.’s five
factors:27 positive, negative, cognitive/disorganized,
affective, and executive.
Patients also used an electronic hand-held tablet to
record the patient-reported outcome (PRO) questionnaires
data. To assure that both assessments were independent,
PRO questionnaires were administered prior to the com-
pletion of other study assessments. Patients completed the
EuroQol-5 Dimension (EQ-5D)21 questionnaire, the Short
Form-36 (SF-36),22 and the Schizophrenia Quality of Life
Scale (SQLS).9
The SF-36 is a generic health status instrument that
measures eight dimensions, namely general health, bodily
pain, physical functioning, role-physical, mental health,
vitality, social functioning, and role-emotional. Out of the
items, a physical and a mental health summary score can
be calculated (SF-36 physical component score, SF-36
PCS, and SF-36 mental component score, SF-36 MCS).
The calculation is such that the population mean of these
summary scores is 50, with higher ratings indicating
a better HRQoL.
The EQ-5D questionnaire has two parts. The first part
consists of five questions on different aspects of HRQoL
(mobility, self-care, usual activities, pain, and anxiety/
depression). This first part allows the calculation of
a health preference measure or tariff with values ranging
from 0 (death) to 1 (perfect health). The second part is
a visual analog scale (EQ-5D VAS) which invites the
responder to mark their current quality of life on a line
from 0 mm (worst imaginable health state) to 100 mm
(best imaginable health state). The EQ-5D population tar-
iffs and SF-36 mental component score (SF-36 MCS) and
physical component score (SF-36 PCS) were calculated
using the UK validation studies.28,29 Both, the SF-36 and
the EQ-5D have been found to have good validity and
reliability in several populations.30–34
The Schizophrenia Quality of Life Scale assesses
HRQoL in three areas: a) psychological features, which
comprises various emotional problems such as feeling lonely,
depressed, or hopeless, and difficulties in social situations or
being worried about the future; b) motivation and energy,
Dovepress Domenech et al
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which includes problems with motivation and activity such
as lacking the drive to do things and engaging in activities
that cause positive experiences; and c) symptoms and side
effects, such as problems with sleeping, blurred vision, dizzi-
ness, muscle twitches, and dry mouth, which can be asso-
ciated with medication.9 The rating of each of the three scales
is recalculated to have a range from 0 to 100 with higher
ratings meaning worse health status. The scale includes 30
items. The internal reliability of the SQLS scale ranges from
0.78 to 0.93 for the three subscales (psychosocial, motivation
and energy and symptoms and side-effects).9
Statistical Analysis
The analyses comprised patients who fulfilled all the elig-
ibility criteria for the cross-sectional phase (N=1,379).
Descriptive analyses were conducted on socio-
demographic, clinical and HRQoL variables. Internal con-
sistency of the scales was estimated using the Cronbach
alpha statistic.35 A Cronbach alpha greater than 0.7 has
been considered satisfactory.36 Scatter plots of the correla-
tions between the HRQoL scales and sub-scales were pro-
vided. Pearson correlation coefficients between the pairs of
HRQoL scales were calculated. The analyses of the baseline
factors associated with HRQoL ratings were estimated using
linear regression models. Given that many individuals had
a rating of 1 in the EQ-5D tariff, Tobit regression was used
to adjust for ceiling effects in this analysis.37 Sex, age, and
country were included in all regression models regardless of
their statistical significance. The rest of the covariates were
chosen based on the relevance and significance in the
descriptive analyses. The following variables were tested:
age at onset, time since onset, PANSS (overall and positive,
negative, cognitive/disorganized, affective and excitement),
number of co-morbidities, type of co-morbidity (cardiovas-
cular, endocrine/metabolic, musculoskeletal, gastrointest-
inal, obesity, genitourinary, respiratory, neurological in
extremities, cancer, hematopoietic, dermatological, and
others), extrapyramidal symptoms, tardive dyskinesia and
akathisia, and substance use (including past or current use
of alcohol, recreational drugs, and other substances). All
statistical analyses were done with SAS version 9.
Results
Patient Characteristics
A total of 1,433 patients were included in the study. They
came from 40 study sites in eight countries (Argentina
N=110, Brazil N=100, Canada N=117, France N=237,
Germany N=250, Italy N=219, Spain N=207, and the
United Kingdom N=139). More than two third of the
patients (71%) were male and the mean age was about
forty years old (Table 1). Four out of ten patients had one
or more co-morbid physical disorders and about
five percent had a current substance use problem. The
mean PANSS overall score was 78 points. The SF-36


























Years since onset 15.07 (10.39)
PANSS Total score 77.98 (22.97)
PANSS Positive score 15.82 (6.44)
PANSS Negative score 22.52 (7.42)
PANSS Cognitive/disorganized score 17.89 (6.02)
PANSS Depression score 12.21 (4.61)
PANSS Excitement score 9.54 (4.22)
SQLS Total score 37.55 (15.55)
SF36 Mental component 40.68 (11.16)
SF36 Physical component 49.88 (8.40)
EQ-5D Tariff score 0.72 (0.21)
EQ-5D VAS score 65.28 (19.61)
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physical component score was 50, similar to the popula-
tion mean, whereas the SF-36 mental component was 41.
Internal Consistency
Cronbach’s alphas were estimated for the scales. The value
for the SQLS was 0.92. The value for the EQ-5D was 0.65.
For the SF-36 subscales, values were 0.90 for Physical func-
tioning, 0.91 for Role physical, 0.83 for Bodily pain, 0.77 for
General health, 0.76 for Vitality, 0.77 for Social functioning,
0.88 for Role emotional, and 0.82 for Mental health.
Factors Associated with Health-Related
Quality of Life
Females consistently reported worse quality of life except
for the EQ-5D tariff, which did not show gender differences
(Table 2). Higher PANSS positive dimension ratings were
associated with worse HRQoL for the SQLS, EQ-5D VAS,
SF-36 MCS, and SF-36 PCS. Higher PANSS negative
dimension ratings were associated with worse HRQoL for
the EQ-5D VAS, SF-36 MCS, and SF-36 PCS, but not for
the SQLS or the EQ-5D tariff. PANSS depression ratings
were associated with lower HRQoL ratings in all the scales.
The other factors presented a less consistent pattern across
the different HRQoL scales. Current substance use was
associated to lower EQ5D tariff, obesity with lower SF-36
MCS ratings but higher SF-36 PCS, the number of physical
comorbidities with both lower EQ5D tariff and SF-36 PCS,
the number of hospitalizations only with lower EQ5D VAS.
Relationships Among Health-Related
Quality of Life Scales
There was a high correlation between the different HRQoL
scales (Figure 1). The highest correlation (Table 3) was
between the SQLS total score and the SF-36 MCS
(Pearson Correlation Coefficient, PCC 0.746), and the low-
est between the EQ5D-VAS and the SF-36 PCS (PCC
0.355). Not included in the figure are the correlations
between EQ-5D VAS and EQ-5D tariff (0.516, p<0.001)
and between SF-36 MCS and SF-36 PCS (0.076, p<0.01).
Discussion
This study has shown substantial agreement between three
health-related quality of life scales, two generic, EQ-5D
and SF-36, and one condition-specific, SQLS, in a large
cross-national sample of patients with schizophrenia. We
have shown that the three scales also tend to show analo-
gous gender differences and vary similarly with the
intensity of the different symptom dimensions in schizo-
phrenia. This provides some support for the use of generic
HRQoL measures in schizophrenia.
Our finding of depressive symptoms as a key determi-
nant of HRQoL in people with schizophrenia is consistent
with many other QoL studies38–41 and confirm they are
negative predictors of HRQoL, with respect to both mental
health and physical components. Previous results have
showed that the effect of depressive symptoms is mostly
present on the mental health component,42 but our findings
are still consistent with the literature as Meijer et al showed
that the mental health component may have an impact on
the physical component.43 The longitudinal study of QoL in
older adults (≥55 years old) from Cohen et al44 has sug-
gested that the relationship between QoL and depressive
symptoms is bidirectional, conversely to other clinical
symptoms, as the increased social isolation because of the
decrease in interactions with friends and peers, reduces self-
reported life satisfaction, and the lower quality of life
impacts on the feelings of the individual. Further studies
on the relationship between depressive symptoms and QoL
are warranted.
Findings on the association of positive symptoms on
QoL have been varied and contradictory, while some have
found associations,41,43–48 many have not.38,49,50 Our
results show that positive symptoms are a negative pre-
dictor of both mental and physical components of quality
of life. One of the reasons most studies have not found
significant results for positive symptoms might be due to
the different QoL measures used: Eack and Newhill’s
meta-analysis suggested that disparate findings might be
due to positive symptoms having strongest relationship
with HRQoL, smaller associations with subjective QoL
and general well-being, and no relationship with objective
QoL.51
The association between negative symptoms and QoL
has been found varying and contrasting too, probably due
to the way negative symptoms have been assessed. The
assessment of QoL may also be relevant in explaining
these diverse results. Subjective and objective HRQoL
measures may have different relationships with negative
symptoms.52 Also, it has been found that apart from the
low correlation between subjective QoL and objective
QoL, their relationships with patient characteristics varies,
which suggests that they may be separate and possibly
complementary constructs.53 Hence, both types of QoL
data are essential. The present study shows that negative
symptoms are significant predictor of lower HRQoL.
Dovepress Domenech et al
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Negative symptomatology represents a highly personal
and social burden for a large number of individuals with
schizophrenia, since they are unable to live independently
and manage everyday social situations. This is more rele-
vant if we consider that negative symptoms are associated
with a limited response to pharmacotherapies, thus, remain
an area of unmet therapeutic need.54
A higher cognitive symptom severity score in the
PANSS scale was associated with a higher EQ-5D rating
and with a higher SF-36 rating. Thus, in our study, patients
with more cognitive problems reported a higher quality of
life on the EQ-5D and the SF-36 scales. This is not con-
sistent with previous studies. For example, population stu-
dies have found that mild cognitive impairment is
associated with lower health-related quality of life.55,56
The results of studies with patients with schizophrenia are
comparable. Apteinin et al57 in a sample of 38 patients with
schizophrenia, found that cognitive deficits, specifically in
executive function and working memory, were associated
with lower self-reported quality of life, in particular in the
social sphere. Analogous results were reported by Savilla
et al in a sample of 57 individuals with schizophrenia.58
However, several of these studies did not adjust for the
severity of other psychiatric symptoms. Our results do
take into account the severity of other symptoms of schizo-
phrenia. Some might be skeptical about the reliability and
validity of self-rated instruments in people with schizophre-
nia due to cognitive deficits. A meta-analysis revealed that
neurocognitive deficits have an insignificant relationship
with subjective QoL (client satisfaction)59 whereas three
recent studies suggest that cognitive deficits, when assessed
from the patients’ point of view, show a significant relation-
ship with QoL.60 This warrants the need to further investi-
gate the role cognition plays in QoL of patients with
schizophrenia.40 Another possible explanation for our find-
ings is that patients with cognitive problems are less aware
of their problems. To elucidate the influence of cognitive
dysfunction on QOL, further studies using neuropsycholo-
gical tests are necessary.61
It is worth noting that approximately forty percent of the
participants in this study reported one or more co-morbid
physical disorders. This is in line with past literature, where
chronic medical conditions, especially cardiovascular diseases
and diabetes, often co-occur with schizophrenia or severe
mental illnesses.62–64 Furthermore, somatic comorbidity
resulted to be associated with poorer HRQoL on EQ5D
TARIFF and SF-36 PCS scales. The study from Sexton at al.
has shown that chronic medical conditions affect QoL via
physical impairment (increased deficits in physical body func-
tion and activity), which is directly and indirectly associated
with reduced positive affect.65 Recently, the prevalence of
a comorbid condition (at least one condition) in patients with
Schizophrenia has been estimated to be approximately 80%.
Furthermore, while an increase in the prevalence of comorbid
conditions was generally observed across all age categories, an
age-specific increase was found in the schizophrenia group as
compared to controls with regard to suicide attempts, diabetes,
and epilepsy. These differences were highly pronounced at
younger ages and decreased with increasing age.66 The mag-
nitude of the problemunderlines the need for regular screening,
comprehensive assessment, preventive pharmacotherapy, and
targeted somatic comorbidity management.
Pearson’s correlation -0.638*** Pearson’s correlation -0.600*** Pearson’s correlation -0.746*** Pearson’s correlation -0.401***
Pearson’s correlation 0.571*** Pearson’s correlation 0.355*** Pearson’s correlation 0.482*** Pearson’s correlation 0.526*** 
Figure 1 Scatter plot figures of the relationship among the quality of life scales. ***p<0.001.
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Other results in the present study are in line with previous
literature, as current substance use and a higher number of
hospitalization have been associated with lower HRQoL.67,68
Regarding obesity, the present study found an association
with absence of obesity and a lower score on SF-36 MCS,
contrary to a higher score on SF-36 PCS: while the associa-
tion between obesity and a lower physical component
HRQoL has been widely documented,69 the association
between obesity and a higher mental component HRQoL is
uncommon. However, obesity can cause developmental pro-
blems, such as poor cognitive function,70 which, in turn, is
associated with higher HRQoL in our study. In conclusion,
the presence of different clinical factors that affect the health-
related quality of life in people with schizophrenia
encourages the adoption of an integrated recovery-oriented
model that considers wider outcomes than schizophrenia
core symptoms as the main goal of treatment.
The analysis of the internal consistency of the scales
also deserves some comment. The internal consistency of
the SQLS and the scales of the SF-36 were good.
However, the Cronbach alpha of the EQ-5D was below
the value of 0.7, which is considered acceptable in group
comparisons. This may be explained by the EQ-5D being
mostly an inventory of symptoms assessing different
dimensions of HRQoL. Although previous studies have
found good reliability measures for the EQ5D,71 other
studies have found lower values than 0.772
In evaluating these findings, we need to take into
account a number of limitations. First, this analysis may
be criticized on the bases that we are comparing two generic
HRQoL scales whose theoretical construct is not exactly the
same as the condition-specific scale. While the first two
include both mental and physical health problems, the
SQLS specifically assesses HRQoL associated with the
Table 3 Association Between QoL Measures
Pearson Correlation Coefficients Prob > |r| under H0: Rho=0
Number Of Observations
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symptoms of schizophrenia and its treatment and how they
impair HRQoL. However, since there is still a debate about
using generic or condition specific HRQoL scales when
assessing treatment effects, we think our results are
informative. Second, as mentioned above, we present
a cross-sectional analysis, and sensitivity to change of the
scales was not assessed. Third, we only evaluated three
scales, two generic and one condition-specific, among the
many that are available. Results with other scales could
have been different. Since these scales and other HRQoL
scales may also lack a common conceptual base agreement
may vary depending on the specific comparison. Fourth, we
included in the study a community sample of patients with
stable symptoms, and the results may be different in patients
presenting a psychotic exacerbation. Fifth, there may be
many other aspects beyond those analyzed in this study
when choosing a preference-based measure.73 Sixth, the
calculation of the PANSS factors was based on the work
by Lindenmayer et al27 but other models could also have
been used.74 Seventh, we have not adjusted for multiple
testing. Eight, we had limited information on contextual
factors that may influence the quality of life, such as psy-
chological aspects and living conditions.75,76 Finally, we
have accepted two types of diagnostic criteria (ICD and
DSM) in the inclusion of patients with schizophrenia.
These diagnostic criteria differ in significant aspects such
as the minimum duration of the disorder to fulfill the diag-
nostic criteria.
These results may be contingent on the HRQoL scales
which were chosen in the evaluation. Previous research has
found that the correlations of HRQoL may differ depending
on the dimensions and particular questions each of the scales
include. When choosing the generic HRQoL scales, we
decided to employ the most widely used scales in Europe
and the USA. To decide which condition-specific HRQoL
scale to employ, we looked for a scale that covered the areas
described by Awad and Voruganti.3 According to Awad and
Voruganti, for HRQoL scales to be relevant in the assessment
of patients with schizophrenia, the outcome should cover the
interaction among three major determinants: psychotic
symptoms and their severity, medication side effects, and
psychosocial performance. We have chosen the SQLS scale
as the disorder-specific scale as it includes those three
dimensions.9 In conclusion, these findings provide some
support for the use of generic HRQoL scales in schizophrenia
and underline the clinical factors that affect the health-related
quality of life in people with schizophrenia: depressive
symptoms, positive and negative symptoms, cognitive
impairment, current substance use and somatic comorbid-
ities. Although there is much debate on whether these scales
capture the health status of individuals with schizophrenia,
this study has shown that, in clinically stable patients, their
ratings correlate at least as much as a condition-specific scale
with the main symptom dimensions of the disorder. Our
results are limited since only cross-sectional relationships
were analyzed.
Conclusion
In conclusion, our study shows that generic and condition-
specific quality of life scales have similar correlates in
patients with schizophrenia, which supports the use of
generic HRQoL scales in schizophrenia.
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